AU2017321011B2 - Dosage regimen for treatment of solid tumors - Google Patents

Dosage regimen for treatment of solid tumors Download PDF

Info

Publication number
AU2017321011B2
AU2017321011B2 AU2017321011A AU2017321011A AU2017321011B2 AU 2017321011 B2 AU2017321011 B2 AU 2017321011B2 AU 2017321011 A AU2017321011 A AU 2017321011A AU 2017321011 A AU2017321011 A AU 2017321011A AU 2017321011 B2 AU2017321011 B2 AU 2017321011B2
Authority
AU
Australia
Prior art keywords
dose
cancer
administered
day
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017321011A
Other languages
English (en)
Other versions
AU2017321011A1 (en
Inventor
Karim Adnane BENHADJI
Eunice Soek Mun Yuen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2017321011A1 publication Critical patent/AU2017321011A1/en
Application granted granted Critical
Publication of AU2017321011B2 publication Critical patent/AU2017321011B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017321011A 2016-08-31 2017-08-24 Dosage regimen for treatment of solid tumors Ceased AU2017321011B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662381911P 2016-08-31 2016-08-31
US62/381,911 2016-08-31
PCT/US2017/048308 WO2018044662A1 (en) 2016-08-31 2017-08-24 Dosage regimen for treatment of solid tumors

Publications (2)

Publication Number Publication Date
AU2017321011A1 AU2017321011A1 (en) 2019-02-21
AU2017321011B2 true AU2017321011B2 (en) 2023-08-03

Family

ID=59772787

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017321011A Ceased AU2017321011B2 (en) 2016-08-31 2017-08-24 Dosage regimen for treatment of solid tumors

Country Status (14)

Country Link
US (1) US20190209581A1 (https=)
EP (1) EP3506905B1 (https=)
JP (2) JP2019526632A (https=)
KR (1) KR102512899B1 (https=)
CN (2) CN109562114A (https=)
AU (1) AU2017321011B2 (https=)
BR (1) BR112019002461A2 (https=)
CA (1) CA3035616A1 (https=)
ES (1) ES2977556T3 (https=)
IL (2) IL264924B2 (https=)
MA (1) MA46086A (https=)
MX (1) MX387397B (https=)
SG (2) SG11201901325UA (https=)
WO (1) WO2018044662A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
ES2881801T3 (es) 2016-04-12 2021-11-30 Lilly Co Eli Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
WO2017180385A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
MA45025A (fr) 2016-05-20 2019-03-27 Lilly Co Eli Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168014A1 (en) * 2015-04-14 2016-10-20 Eli Lilly And Company Targeted treatment of leiomyosarcoma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US46206A (en) 1865-02-07 Improved vessel for holding petroleum
WO2008112249A1 (en) * 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
EP2214679B1 (en) * 2007-11-13 2019-03-27 Meritage Pharma, Inc. Corticosteroid compositions
AR087107A1 (es) 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
CA2952315A1 (en) * 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168014A1 (en) * 2015-04-14 2016-10-20 Eli Lilly And Company Targeted treatment of leiomyosarcoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHE MASSARD: "First-in-human study of LY3039478, a Notch signaling inhibitor in advanced or metastatic cancer", JOURNAL OF CLINICAL ONCOLOGY: VOL 33, NO 15_SUPPL, *
EUNICE YUEN: "Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in the first-in-man study", CANCER RESEARCH, 1 July 2016 (2016-07-01), XP055417836, Retrieved from the Internet [retrieved on 20171020] *

Also Published As

Publication number Publication date
AU2017321011A1 (en) 2019-02-21
SG11201901325UA (en) 2019-03-28
BR112019002461A2 (pt) 2019-05-14
IL264924B1 (en) 2023-09-01
EP3506905A1 (en) 2019-07-10
EP3506905B1 (en) 2024-03-20
CA3035616A1 (en) 2018-03-08
IL264924B2 (en) 2024-01-01
KR20190042591A (ko) 2019-04-24
MA46086A (fr) 2019-07-10
JP2019526632A (ja) 2019-09-19
WO2018044662A1 (en) 2018-03-08
JP2023052108A (ja) 2023-04-11
ES2977556T3 (es) 2024-08-26
IL264924A (https=) 2019-04-30
KR102512899B1 (ko) 2023-03-23
US20190209581A1 (en) 2019-07-11
MX387397B (es) 2025-03-18
SG10202107832UA (en) 2021-09-29
IL305136A (en) 2023-10-01
CN116473978A (zh) 2023-07-25
MX2019002066A (es) 2019-06-03
CN109562114A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
AU2017321011B2 (en) Dosage regimen for treatment of solid tumors
US12478601B2 (en) Dietary product devoid of at least two non essential amino acids
TWI631950B (zh) 藉二氫吡𠯤并吡𠯤治療癌症
JP6995058B2 (ja) （１ｓ，４ｓ）－４－（２－（（（３ｓ，４ｒ）－３－フルオロテトラヒドロ－２ｈ－ピラン－４－イル）アミノ）－８－（（２，４，６－トリクロロフェニル）アミノ）－９ｈ－プリン－９－イル）－１－メチルクロロヘキサン－１－カルボキサミドの固体形態及びその使用方法
JP6716585B2 (ja) 結腸直腸癌の処置に使用するためのアピリモド
CN112955130A (zh) 包含取代茚满的固体分散体和药物组合物及其制备和使用方法
JP2022500479A (ja) Ｃｄｃ７阻害剤を含む癌の治療方法
TW201722427A (zh) 用於治療癌症之ｍｄｍ２抑制劑的給藥方案
EP3758678A1 (en) Methods of treatment of cancer comprising chk1 inhibitors
EP4213852A1 (en) Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
HK40009858A (en) Dosage regimen for treatment of solid tumors
HK40009858B (en) Dosage regimen for treatment of solid tumors
NZ791442A (en) Dosage regimen for treatment of solid tumors
SG11202112254YA (en) Methods of treating cancer using chk1 inhibitors
TW202434251A (zh) 治療癌症之療法
CN105579458A (zh) 在正电子发射断层摄影术(pet)扫描中使用利福昔明的方法
WO2024186693A1 (en) Methods of treating cancer with a ras mutation
KR20250171183A (ko) 암의 예방 또는 치료용 약제학적 조성물
HK40096504A (en) Dietary product devoid of at least two non essential amino acid
Dienstmann et al. First-in-man dose-escalation study of the selective BRAF inhibitor RG7256 in patients with BRAF V600-mutated advanced solid tumors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired